Evidence map›Paper›PMID 35404959›Full record

ArticlePLoS pathogens2022

Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques.

Alexandra C Willcox, Kevin Sung, Meghan E Garrett, Jared G Galloway, Jesse H Erasmus, Jennifer K Logue, David W Hawman, Helen Y Chu, Kim J Hasenkrug, Deborah H Fuller and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. phippery: a software suite for PhIP-Seq data analysis.Bioinformatics (Oxford, England) · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alexandra C WillcoxHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID 0000-0001-6037-6841
Kevin SungPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Meghan E GarrettHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Jared G GallowayPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Jesse H ErasmusDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Jennifer K LogueDepartment of Medicine, University of Washington, Seattle, Washington, United States of America.
David W HawmanLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Helen Y ChuDepartment of Medicine, University of Washington, Seattle, Washington, United States of America.
Kim J HasenkrugLaboratory of Persistent Viral Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Deborah H FullerDepartment of Microbiology, University of Washington, Seattle, Washington, United States of America.
Frederick A Matsen IvPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Julie OverbaughHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID 0000-0002-0239-9444
University of Washington · USFred Hutch Cancer Center · USNational Institutes of Health · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Comprehensive profiling of SARS-CoV-2 antibody responses and escape pathwaysR01AI138709 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OVERBAUGH, JULIE M. · 2018 to 2022
$5.0M
Blending deep learning with probabilistic mechanistic models to predict and understand the evolution and function of adaptive immune receptorsR01AI146028 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MATSEN, FREDERICK ALBERT · 2019 to 2024
$3.4M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
SARS-CoV-2 Immunology and TherapeuticsZIAAI001277 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2020 to 2022
$109k
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI138709NIAID NIH HHS R01 AI146028NIH HHS P51 OD010425NIH HHS S10 OD028685
6 · The paper itself

Abstract

Macaques are a commonly used model for studying immunity to human viruses, including for studies of SARS-CoV-2 infection and vaccination. However, it is unknown whether macaque antibody responses resemble the response in humans. To answer this question, we employed a phage-based deep mutational scanning approach (Phage-DMS) to compare which linear epitopes are targeted on the SARS-CoV-2 Spike protein in convalescent humans, convalescent (re-infected) rhesus macaques, mRNA-vaccinated humans, and repRNA-vaccinated pigtail macaques. We also used Phage-DMS to determine antibody escape pathways within each epitope, enabling a granular comparison of antibody binding specificities at the locus level. Overall, we identified some common epitope targets in both macaques and humans, including in the fusion peptide (FP) and stem helix-heptad repeat 2 (SH-H) regions. Differences between groups included a response to epitopes in the N-terminal domain (NTD) and C-terminal domain (CTD) in vaccinated humans but not vaccinated macaques, as well as recognition of a CTD epitope and epitopes flanking the FP in convalescent macaques but not convalescent humans. There was also considerable variability in the escape pathways among individuals within each group. Sera from convalescent macaques showed the least variability in escape overall and converged on a common response with vaccinated humans in the SH-H epitope region, suggesting highly similar antibodies were elicited. Collectively, these findings suggest that the antibody response to SARS-CoV-2 in macaques shares many features with humans, but with substantial differences in the recognition of certain epitopes and considerable individual variability in antibody escape profiles, suggesting a diverse repertoire of antibodies that can respond to major epitopes in both humans and macaques. Differences in macaque species and exposure type may also contribute to these findings.

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19 VaccinesEpitopesHumansMacaca mulattaSpike Glycoprotein, CoronavirusVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35404959
PMCPMC9022802
OpenAlexW4223415813

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.